


CoagCareTM - Rapid, Point-of-Care Viscoelastic Diagnostic Platform for Prolonged Care of Hemorrhage in the Battlespace



Abhishek Ramkumar, CEO, Founder Abram Scientific, Inc., South San Francisco, California, USA

OPERATIONAL RELEVANCE




WHAT: Hand-held, rapid blood coagulation diagnostic as a fast, decision support tool for treatment of traumainduced coagulopathy or hemorrhage.

WHY: Improve pre-hospital / prolonged care and reduce morbidity and mortality rates.

- Critical decision support diagnostics to triage survivable hemorrhage can greatly improve effectiveness in prolonged care (24-72 hours in austere conditions) through:
 - o Early detection of trauma-induced coagulopathy (TIC).
 - o Adjudication of appropriate use of limited blood products and pharmaceuticals.
- Viscoelastic diagnostics-guided decision support enables targeted resuscitation via point-of-care (POC) monitoring of coagulation status, leading to improved clinical outcomes.
 - A retrospective analysis of the DoD Trauma Registry from 2008 to 2016 (3,320 patients) showed that viscoelastic diagnostics-guided targeted transfusions led to a 57% reduction in overall mortality.




Mortality Rates Stratified Groups from Propensity Scored Cohorts: Non-Viscoelastic Testing (Non-VET) vs. Viscoelastic Testing (VET)




UNIQUE EXPERTISE AND CAPABILITIES

(a) CoagCare Viscoelastic Diagnostic Platform:



(b) Typical viscoelastic curve measured by the CoagCare system in 5-10 minutes, alongside the following parameters:



<parameter unavailable>

LY30: Lysis at 30 minutes

Platelet Contraction (Plt-Cont, sec⁻¹)

Fibrinolysis Rate (Lys-Rate, %)

Abram's CoagCareTM is a first-ofits-kind coagulation platform designed to deliver (1) a goldstandard, viscoelastic method and (2) a rapid, portable, low-cost, meter-card system.

CoagCareTM features:

- 1. Handheld, battery-operated system with low SWAP
- 2. Rapid results in 5-10 minutes, >6x faster than currently labbased systems
- 3. Insensitive to ambient vibrations and noise
- 4. Low blood volume requirement (1 drop ~ 20 μl)
- 5. Low-cost meter & disposable platform capable of performing 5 different coagulation tests + Hct (i.e., TEG, PT, aPTT, ACT, DOACs).

CoagCareTM is not yet FDA approved for sale in the U.S.

OPERATIONAL IMPACT

CoagCareTM guided decision support can revolutionize prolonged care:

- Maximizing care for many wounded warfighters by early detection & management of TIC.
- Targeted resuscitation with precise blood products and pharmaceuticals.
- Optimization of transfusion products for enhanced prolonged care by conservation and optimal distribution across many casualties.

SUPPORT

If you are interested in sponsoring Abram Scientific's efforts, please contact MTEC.



\$3M, CDMRP Award ID#W81XWH2110013



\$2M, SBIR Phase I & II Award ID# 2050272



\$2.5M, Seed Financing Led by Private Equity

CONTACT



Abhishek Ramkumar CEO. Founder Abram Scientific, Inc. aramkumar@abramscientific.com